20-F: CollPlant Biotechnologies Faces Going Concern Doubt Amid Losses

CollPlant Biotechnologies reports a $11.5 million net loss for 2025, driven by R&D investments and cost-cutting, while advancing rhCollagen-based products and securing new funding.

Summary

• Incurred a net loss of $11.5 million for the year ended December 31, 2025, an improvement from $16.6 million in 2024.
• Accumulated deficit reached $124.8 million as of December 31, 2025.
• Revenues increased to $2.4 million in 2025 from $0.5 million in 2024, primarily due to a $2 million development milestone payment from AbbVie.
• Cash and cash equivalents stood at $5.6 million as of December 31, 2025, down from $11.9 million in 2024.
• Experienced negative cash flow from operating activities of $9.4 million in 2025.
• Management has concluded that substantial doubt exists regarding the company's ability to continue as a going concern due to insufficient liquidity for the next 12 months.
• Implemented a cost-cutting and workforce reduction plan in Q4 2025, resulting in an additional 27% reduction in workforce.
• Successfully completed a registered direct offering in June 2025, raising $3.6 million in gross proceeds, and another in February 2026, raising $2 million in gross proceeds.
• AbbVie is currently reviewing interim results from clinical trials for the dermal and soft tissue filler product candidate, with next steps pending their assessment.
• Announced positive non-clinical results for its photocurable dermal filler in September 2025 and plans to advance it into clinical trials.
• Strategically positioned its photocurable dermal filler platform to address facial volume loss associated with rapid weight reduction, including patients treated with GLP-1 therapies.
• Pre-clinical studies for 3D-bioprinted breast implants continue to show encouraging results, with MRI and ultrasound analyses in 2025 and 2024 confirming tissue integration and vascularization.
• Expanded its agreement with STEMCELL in June 2025 to include clinical development and commercial-scale manufacturing of its rhCollagen.
• Launched BioFlex, a ready-to-print rhCollagen-based kit for Digital Light Processing (DLP) 3D bioprinting applications, in February 2026.
• Received a written notice from Nasdaq on March 23, 2026, indicating non-compliance with the minimum bid price requirement ($1.00 per share) and has until September 21, 2026, to regain compliance.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a challenging period for CollPlant, marked by ongoing significant losses, negative cash flows, and a 'going concern' warning from its auditors. While product development shows promise and some funding has been secured, the immediate financial instability and Nasdaq compliance issues present substantial headwinds.

Positives

• Reduced net loss from $16.6 million in 2024 to $11.5 million in 2025.
• Increased revenues in 2025 to $2.4 million, primarily driven by a $2 million development milestone payment from AbbVie.
• Successfully completed registered direct offerings in June 2025 ($3.6 million gross proceeds) and February 2026 ($2 million gross proceeds).
• Achieved a $2 million development milestone payment from AbbVie in February 2025 for the dermal and soft tissue filler product candidate.
• Announced positive non-clinical results for its photocurable dermal filler in September 2025, with plans to advance to clinical trials.
• Strategically positioned its photocurable dermal filler platform to address facial volume loss from GLP-1 therapies, tapping into an emerging market need.
• Pre-clinical studies for 3D-bioprinted breast implants continue to yield encouraging results, demonstrating tissue integration and vascularization.
• Expanded its agreement with STEMCELL in June 2025 to broaden the use of rhCollagen beyond research to include clinical development and commercial-scale manufacturing.
• Launched BioFlex, a ready-to-print rhCollagen-based kit for DLP 3D bioprinting applications, in February 2026.
• CE marking certification for VergenixFG extended to December 31, 2028, and VergenixSTR to December 31, 2027.
• The scope of ISO 13485 certification was extended in July 2023 to cover medical aesthetics products.
• Joined the United National Global Compact in September 2023 and released its inaugural ESG and Sustainability Report in July 2024, highlighting commitment to sustainability.

Negatives

• Incurred significant losses since inception, with a total comprehensive loss of $11.5 million in 2025 and $16.6 million in 2024.
• Accumulated deficit of $124.8 million as of December 31, 2025.
• Negative operating cash flows of $9.4 million in 2025.
• Management has concluded that substantial doubt exists about the company's ability to continue as a going concern.
• Implemented a workforce reduction plan in Q4 2025, cutting an additional 27% of its workforce.
• Received a Nasdaq notice on March 23, 2026, for non-compliance with the minimum bid price requirement ($1.00 per share).
• AbbVie is conducting a review of interim results for the dermal filler, with next steps to be determined, indicating potential uncertainty or delay in the program's advancement.
• Experienced a temporary shutdown of its Yessod Hamaala manufacturing facility in early 2024 due to mechanical failure.
• Took precautionary measures to close its Yessod Hamaala facility for an extended period during 2024 due to the war and its proximity to the border with Lebanon.
• Temporarily deferred the development of injectable breast implants and RTM to concentrate efforts on 3D-bioprinted regenerative breast implants.
• Put the 'Gut-on-a-Chip' program on hold to focus resources on other priorities.
• Missing permits for certain structures at the Yessod Hamaala production site, which could lead to a halt or closure of the site.

Risks

• History of significant losses and anticipation of continued losses for the foreseeable future.
• Need to raise additional funding, which may not be available on acceptable terms or at all, potentially forcing delays, limitations, or termination of product development efforts.
• Substantial doubt about the ability to continue as a going concern, which could prevent obtaining new financing on reasonable terms.
• Commercial success of any current or future product depends on market acceptance by physicians, patients, third-party payors, and the medical community.
• Limited clinical data to support sales of products, potentially leading to reluctance from the medical community to accept or purchase.
• Low-scale experience in producing rhCollagen; inability to manufacture in high commercial quantities successfully and consistently could limit growth.
• Inability to establish sales and marketing capabilities or enter into agreements with third parties could prevent generation of material revenue.
• Facing intense competition and rapid technological change from competitors who may develop more advanced or effective therapies.
• Heavy dependence on the future success of medical aesthetics, 3D bioprinting product candidates, and bioink products.
• Novel technology makes it difficult to predict the time and cost of product development and potential regulatory approval.
• Difficulty enrolling patients in future clinical trials or patient discontinuation could delay or prevent clinical trials.
• Clinical trials conducted by the company or strategic partners may not be successful or may be delayed.
• Products will remain subject to regulatory scrutiny even if regulatory approval is obtained.
• Future prospects are dependent on the ability to successfully develop a pipeline of additional products, which may not be successful.
• Inability to establish and maintain strategic partnerships could adversely affect the ability to develop and commercialize rhCollagen-based products.
• Expectation to depend upon third-party collaborators, distributors, and resellers for a significant portion of sales.
• Reliance on third parties to conduct some aspects of product manufacturing, protocol development, research, and preclinical/clinical testing, with risks of unsatisfactory performance.
• Future success depends on the ability to retain senior management, consultants, and advisors, and to attract, retain, and motivate qualified personnel.
• Collaborations with outside scientists and consultants may be subject to restriction and change.
• Business and operations would suffer in the event of computer system failures or security breaches.
• Development and production of rhCollagen relies upon the continued availability of tobacco plants; any interruption could delay production.
• Damage or destruction of existing rhCollagen production sites or any new facilities, or production interruptions, would negatively affect business.
• Failure to comply with environmental, health, and safety laws and regulations could lead to fines, penalties, or significant costs.
• Financial and human resources may be used to pursue a particular research program or product and fail to capitalize on more profitable opportunities.
• Exposure to foreign currency exchange risk, particularly fluctuations between the U.S. dollar and the NIS and Euro.
• Business, operating results, and growth rates may be adversely affected by current or future unfavorable economic and market conditions and associated liquidity risk.
• Environmental, social, and corporate governance (ESG) issues may have an adverse effect on business and damage reputation.
• High cost and continuous review required for maintaining an extensive worldwide patent portfolio.
• Inability to obtain or protect intellectual property rights related to products and product candidates could prevent exclusivity or allow competitors.
• Market price of ordinary shares may be highly volatile.
• Inability to maintain listing on the Nasdaq Capital Market, including compliance with minimum bid price requirements.
• Incurring significant additional costs as a public company subject to SEC reporting requirements.
• Principal shareholders, management, and directors beneficially own a significant percentage of ordinary shares and can exert significant influence.
• Failure to maintain an effective system of internal control over financial reporting could harm business and share price.
• Sales of a substantial number of ordinary shares in the public market could cause the share price to fall.
• Future sales and issuances of securities or rights to purchase securities could result in additional dilution of percentage ownership.
• No intention to pay dividends on securities in the foreseeable future, limiting returns to share value appreciation.
• Percentage ownership may be diluted by future issuances of share capital.
• If equity research analysts do not publish research reports or issue unfavorable commentary, the price of ordinary shares could decline.
• As a foreign private issuer, following certain home country corporate governance practices may provide less protection to shareholders than U.S. domestic issuers.
• The security situation in the State of Israel, where the majority of senior management and R&D facilities are located, may adversely impact results of operations.
• Tax benefits available may be prevented or reduced in the future, increasing costs and taxes.
• Difficulty enforcing a U.S. judgment against the company, its officers, and directors in Israel or asserting U.S. securities laws claims in Israel.
• Shareholder rights and responsibilities are governed by Israeli law, which may differ from U.S. corporations.
• Provisions of Israeli law and the amended and restated articles of association could make it more difficult or costly for a third party to acquire the company.
• Potential classification as a passive foreign investment company (PFIC) for U.S. federal income tax purposes, leading to adverse tax consequences for U.S. shareholders.
• Facilities in Israel are subject to local Business Licensing and Planning and Zoning regulations, and missing permits for certain structures at the Yessod Hamaala production site could adversely impact operations.

Future Outlook

The company expects to continue incurring significant expenses and operating losses in the foreseeable future, with expenses increasing as research, preclinical, and clinical development advance. Future revenues are dependent on regulatory approvals, market acceptance, and reimbursement. The transition to profitability is contingent upon the successful development and commercialization of products, establishment of new distribution contracts, and strategic partnerships. The company's current cash flow and resources are not sufficient to fund operations for the next 12 months, necessitating additional financing.

Management Comments

• We are a regenerative and aesthetic medicine company focused on medical aesthetics and 3D bioprinting of tissues and organs.
• We believe our proprietary rhCollagen serves as the ideal building block for regenerative medicine.
• We believe our technology is the only commercially viable technology available for the production of genetically engineered, or recombinant, human collagen.
• We believe the clinical attributes of our rhCollagen will translate into benefits for patients, payors, and physicians, and will be adopted rapidly by the market.
• We believe that the demand for tissue-derived collagen will decrease as the market recognizes the significant advantages of our rhCollagen.
• Our management holds regular research and development meetings where they prioritize development projects and determine future products.
• We believe that our existing facilities are adequate for our near-term needs.
• We believe that suitable additional or alternative space and area would be available if required in the future on commercially reasonable terms.
• We believe that our environmental, health, and safety procedures for handling and disposing of these materials comply with the standards prescribed by the controlling laws and regulations.
• We believe our employee relations are good.
• We believe that such activities may facilitate future collaborations and partnerships pursuant to which we would supply rhCollagen for use in such products, potentially in return for royalties.
• We are not aware of any impediments to the patent applications being granted in the United States or other jurisdictions.
• We are currently not a party to any material legal or administrative proceedings and, are not aware of any pending or threatened material legal or administrative proceedings against us.
• As of the date of this report, we have not, to our knowledge, experienced any material IT system failures or any material cybersecurity attacks, and we are not aware of any material risks from cybersecurity threats that have materially affected or are reasonably likely to materially affect us, including our business strategy, results of operations or financial condition.

Industry Context

StockSavvy.ai notes that CollPlant operates in the rapidly evolving regenerative and aesthetic medicine fields, characterized by intense competition from major pharmaceutical, biotechnology, and medical technology companies. The company's focus on recombinant human collagen (rhCollagen) positions it in a niche with potential advantages over traditional animal-derived collagen, addressing growing markets like dermal fillers (projected $14.19 billion by 2033), breast implants ($4.3 billion by 2034), and 3D bioprinting ($5.3 billion by 2030). The strategic positioning of its photocurable dermal filler for GLP-1 therapy-related facial volume loss taps into a new, emerging market trend. The expansion of the STEMCELL agreement for clinical and commercial use of rhCollagen aligns with the broader industry trend of utilizing advanced biomaterials in regenerative medicine research and development.

Comparison to Industry Standards

• CollPlant's rhCollagen is stated to be structurally and functionally identical to human Type I collagen, offering superior bio-functionality, high homogeneity, and a better safety profile (non-immunogenic) compared to tissue-derived collagens (bovine, porcine, human cadaveric).
• Preclinical studies of CollPlant's photocurable regenerative dermal filler demonstrated superior tissue regeneration, lifting capacity, and volume retention compared to a commercial standard.
• In a head-to-head comparative study, CollPlant's rhCollagen-based bioink, Collink.3D, outperformed Matrigel, a leading extracellular matrix, in supporting structured tissue formation. The global market for basement membrane matrices (including Matrigel) was valued at approximately $96 million in 2024 and is projected to reach $201 million by 2031.
• Clinical trial results for VergenixSTR showed an average 51% and 59% reduction in pain and improvement in motion at three and six months, respectively, compared to 48% and 36% for steroid patients in a 2010 American Journal of Sports Medicine (AJSM) study.
• VergenixFG clinical trial showed 94% median wound area reduction and 50% pain reduction in patients with hard-to-heal chronic wounds, with an 83.3% healing rate and shorter healing time compared to standard treatment in an investigator-initiated study.
• The company's rhCollagen production process using genetically engineered tobacco plants is presented as the only commercially viable technology for mass production of Type I rhCollagen, offering a sustainable and ethical approach compared to traditional animal-derived sources.

Management Changes

Corporate Governance

Legal Proceedings

• Currently not a party to any material legal or administrative proceedings.
• Not aware of any pending or threatened material legal or administrative proceedings against the company.

Related Party Transactions

• Agreements with Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. regarding intellectual property rights for rhCollagen, where Prof. Oded Shoseyov (former Executive Chief Scientist) has a personal interest.
• Contract with wholly-owned subsidiary CollPlant Ltd. for management and administrative services, with CollPlant Ltd. paying the Company NIS 400,000 on a monthly basis.
• Investment agreement with CollPlant Ltd. in November 2024, including previous cash investments and ensuring total investment in the subsidiary constituted at least 80% of the company's total assets by December 31, 2024, to comply with Israel Tax Authority requirements for specific tax benefits.
• Indemnification agreements with current directors and executive officers, exempting them from a breach of their duty of care and undertaking to indemnify them for liabilities, approved by shareholders on July 18, 2023.
• Share-based compensation granted to certain officers and directors under equity compensation plans.

Stakeholder Impact

• Shareholders face potential dilution from future equity issuances, risk of delisting from Nasdaq due to minimum bid price non-compliance, and volatility in share price. Returns are limited to share appreciation as no dividends are planned.
• Employees have been affected by workforce reductions, with an additional 27% reduction in Q4 2025, and may experience further impacts from the security situation in Israel.
• Customers may benefit from new and improved products in medical aesthetics and 3D bioprinting, but product delays or lack of market acceptance could affect availability.
• Suppliers, particularly tobacco plant growers and other third-party vendors, face potential disruptions if manufacturing operations are impacted by mechanical failures or geopolitical events.
• Creditors may have concerns regarding the company's ability to meet existing and future obligations, given the 'going concern' doubt and negative cash flows.

Next Steps

• AbbVie to determine next steps for the dermal and soft tissue filler program after reviewing interim clinical trial results.
• Advance photocurable dermal filler product candidate into clinical trials.
• Continue to optimize regenerative breast implants to ensure longevity and remodeling of neo-tissue.
• Plan to continue to optimize the implant design and apply this design to a pivotal large-animal study for 3D-bioprinted breast implants, intended for discussion with the FDA.
• Revisit the 'Gut-on-a-Chip' program once resources become available.
• Continue with the plan to upgrade production site into a large-scale integrated facility once there is a surge in demand and necessary funds are secured.
• Continue increasing awareness of rhCollagen through clinical trial data publication, marketing studies, and participation in conferences.
• Obtain new CE-certificates under the MDR before current ones expire.
• Monitor the closing bid price of ordinary shares and consider options to regain compliance with Nasdaq minimum bid price rule, including a reverse stock split.
• Continue to monitor the security situation in Israel and examine potential disruptions.
• Continue correspondence with relevant authorities to obtain necessary permits for Yessod Hamaala production site structures.

Key Dates

Recommendation

CollPlant faces significant financial challenges, including recurring losses, negative operating cash flows, and a 'going concern' warning from its auditors. The recent Nasdaq delisting notice for minimum bid price non-compliance adds further pressure. While product development shows promise and some funding has been secured, the company's immediate liquidity issues and the high-risk nature of its R&D-heavy business model suggest a 'sell' recommendation for investors seeking stability and clear profitability pathways.

Keywords

Regenerative medicine, Medical aesthetics, 3D bioprinting, rhCollagen, Recombinant human collagen, Dermal fillers, Breast implants, Bioink, Tissue engineering, CollPlant, CLGN, Biotechnology, Pharmaceuticals, Israel, SEC filing, Annual Report, Nasdaq